UNITED THERAPEUTICS overview

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that ten posters and presentations across its commercial and development portfolio will be presented at the International Society for Heart and Lung Transplantation ( ISHLT ) 45 th Annual Meeting and Scientific Sessions taking place April 27 through April 30, 2025 in Boston. “The additional data across our portfolio presented at this year’s meeting highlight our commitment to furthering the science...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best Companies to Work For® in 2025. United Therapeutics ranked number 73 out of the 100 companies across the nation included in the list. “We are honored to be recognized by Fortune as one of the 100 Best Companies to Work For,” said Michael Benkowitz , President & Chief Operating Officer of United...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that James Edgemond , Chief Financial Officer and Treasurer, will provide an overview and update on the company’s operations during a fireside chat session at the Leerink Partners Global Healthcare Conference 2025 in Miami Beach. The session will take place on Tuesday, March 11, 2025, from 10:00 a.m. to 10:30 a.m., Eastern Daylight Time, and can be accessed via a live webcast on the United...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. “I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue,” said Martine Rothblatt, Ph.D. , Chairperson and Chief Executive Officer of United...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Michael Benkowitz , President and Chief Operating Officer, will provide an overview and update on the company’s operations during a fireside chat session at the TD Cowen 45 th Annual Health Care Conference in Boston. The session will take place on Monday, March 3, 2025, from 1:50 p.m. to 2:20 p.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website...

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its fourth quarter and full year 2024 financial results before the market opens on Wednesday, February 26, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, February 26, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced full enrollment of the TETON 1 study evaluating the use of Tyvaso® (treprostinil) inhalation solution ( nebulized Tyvaso ) for the treatment of idiopathic pulmonary fibrosis ( IPF ). The TETON 1 study enrolled 598 patients and is part of the three-study global TETON clinical trial program evaluating the use of inhaled treprostinil in IPF and a similar condition, progressive pulmonary fibrosis ( PPF ). TETON...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that five posters across its commercial and development portfolio in pulmonary hypertension ( PH ) will be presented at the Pulmonary Vascular Research Institute ( PVRI ) 2025 Annual Congress taking place January 29 through February 1, 2025 in Rio de Janeiro. In addition, professionals from United Therapeutics will participate in two speaking events associated with the congress. United Therapeutics is...